Mapping the genomic landscape of Type 2 diabetes

NewsGuard 100/100 Score

In the largest genome-wide association study to date on Type 2 diabetes, a team of international researchers, co-led by a University of Massachusetts Amherst genetic epidemiologist, has located 1,289 genetic markers associated with Type 2 diabetes (145 of which are newly identified) and generated risk scores for diabetes complications.

In research published Monday, Feb. 19 in the journal Nature that advances understanding into the inheritability of Type 2 diabetes, the scientists used cutting-edge computational approaches to identify eight distinct mechanistic clusters of genetic variants linked to the disease. They also discovered associations between individual clusters and diabetes complications.

We tried to figure out some of the mechanisms for how these genetic variants are working – and we did."

Cassandra Spracklen, co-senior author, assistant professor of biostatistics and epidemiology in the School of Public Health and Health Sciences

Ultimately, the goal is to identify potential genetic targets to treat or even cure the chronic metabolic disease that affects and sometimes debilitates more than 400 million adults worldwide, according to the International Diabetes Federation.

The study – emerging from the newly formed Type 2 Diabetes Global Genomics Initiative – included data from a highly diverse group of more than 2.5 million individuals, 428,452 of whom have Type 2 diabetes. 

"We found eight clusters of Type 2 diabetes-associated variants that have also been associated with other diabetes risk factors – such as obesity and liver-lipid metabolism – suggesting the mechanisms for how the variants may be acting to cause diabetes," Spracklen says. "Then we asked if these clusters were also associated with Type 2 diabetes complications? And we found that several of them to also associated with vascular complications, such as coronary artery disease and end-stage diabetic nephropathy."

Even though effective treatments are available for Type 2 diabetes, the option for precision medicine tailored to the individual is still limited. For many people with the disease, treatment strategies still rely on trial and error. Being better able to understand the disease mechanisms will help predict individuals' risk of Type 2 diabetes and allow for earlier intervention.

"We're trying to understand how diabetes develops," says Spracklen, adding that the new research includes data from cohorts not available in an earlier genome-wide association study published in 2022 in Nature Genetics, for which Spracklen was co-first author. "And we're trying to better understand how these genetic variants are actually working within a biological tissue or at the cellular level, which can ultimately lead to new drug targets and treatments." 

Senior corresponding author Eleftheria Zeggini, director of the Institute of Translational Genomics at Helmholtz Munich and a professor at the Technical University of Munich, notes that collaboration among scientists is essential for evaluating vast patient data and achieving a comprehensive understanding of genomic risk variants. 

"The genetic information in our cells harbors secrets about the risks, progression and complications of many diseases," she says. "Our work leads to an improved understanding of disease-causing biological mechanisms. Better knowledge of progression risk for Type 2 diabetes complications can help put in place early interventions to delay or even prevent these debilitating medical conditions."

The paper concludes, "Our findings … may offer a route to optimize global access to genetically informed diabetes care." 

Journal reference:

Suzuki, K., et al. (2024). Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Healthy eating, physical activity, and medication: Type 2 diabetes patients' willingness to engage varies